0
0
Read Time:5 Minute, 47 Second
PHILADELPHIA — Researchers at the University of Pennsylvania have developed an experimental bioengineered chewing gum that significantly reduced levels of human papillomavirus (HPV) and two cancer-linked oral bacteria in preliminary laboratory tests. The study, published in Scientific Reports, demonstrates a novel approach to trapping and neutralizing harmful microbes directly inside the oral cavity. However, medical experts and public health authorities emphasize that while these lab findings offer an intriguing proof-of-concept, the experimental gum has not been tested in living human beings, is not commercially available, and cannot prevent, treat, or cure head and neck cancer.
Key Findings: Bioengineered Beans and Microbial Traps
The research team, led by Dr. Henry Daniell at the University of Pennsylvania’s School of Dental Medicine, investigated ways to target microbes implicated in head and neck squamous cell carcinoma (HNSCC). HNSCC represents a group of malignancies arising in the moist linings of the mouth, throat, voice box, and surrounding structures.
To create the experimental product, investigators utilized plant materials derived from lablab beans (also known as hyacinth beans). These beans naturally produce a specialized plant protein called FRIL, which possesses potent antiviral properties. In laboratory settings, researchers exposed patient saliva and oral-rinse samples to extracts from the formulated chewing gum to evaluate its ability to clear viral particles.
The laboratory results were striking:
-
HPV Reduction in Saliva: The gum extract reduced detectable HPV levels by approximately 93% in saliva samples collected from HNSCC patients.
-
HPV Reduction in Oral Rinses: The extract reduced HPV levels by 80% in oral-rinse samples.
-
Viral Aggregation: In several samples, the plant protein caused viral particles to clump together (aggregate), potentially facilitating their removal from oral tissue.
To target bacterial threats, the team incorporated an antimicrobial peptide named protegrin-1 into the formulation. This addition specifically targeted Porphyromonas gingivalis and Fusobacterium nucleatum—two key bacterial species associated with severe periodontal disease and worse overall outcomes in head and neck cancers. Following a single laboratory exposure, both bacterial populations fell to nearly undetectable levels.
Critically, the research team observed that the formulation caused minimal disruption to beneficial, capsule-forming bacteria that make up a healthy oral microbiome. Maintaining these friendly microbes is vital, as indiscriminate antimicrobial action can compromise natural oral defenses.
The Link Between HPV, Oral Bacteria, and Cancer Risk
Understanding why researchers are targeting these specific microbes requires examining how head and neck cancers develop.
Human papillomavirus, particularly high-risk strain HPV16, is a major driver of oropharyngeal cancers—cancers affecting the tonsils, the base of the tongue, and the back of the throat. According to the National Cancer Institute, persistent high-risk HPV infection is a well-established cause of these malignancies. Unlike traditional head and neck cancers that historically affected older individuals with long histories of heavy tobacco and alcohol use, HPV-positive oropharyngeal cancers have risen rapidly among younger demographics in North America and Europe.
At the same time, chronic inflammation driven by harmful mouth bacteria can create an environment that encourages cancer progression. Pathogens like P. gingivalis and F. nucleatum promote persistent gum inflammation and tissue breakdown. Research published in Oral Oncology indicates that indicators of strong oral hygiene—such as brushing daily, maintaining natural teeth, and receiving regular dental care—are associated with modestly lower odds of developing head and neck cancers.
However, health organizations including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) stress that tobacco products, excessive alcohol consumption, and areca nut (betel quid) chewing remain the primary preventable causes of cancers of the oral cavity.
Expert Caution: Why Lab Results Are Not Human Proof
Despite the encouraging numbers reported in the laboratory, oncologists and infectious disease specialists urge caution against overinterpreting the findings.
The primary limitation rests on the study’s design: it was an ex vivo experiment. No human patients actually chewed the experimental gum. Instead, researchers collected fluid samples from patients and treated those samples in test tubes and petri dishes under strictly controlled laboratory conditions.
Extrapolating test-tube results to a living human body involves significant medical uncertainties:
-
The Dynamic Oral Environment: The human mouth is constantly active. Salival flow, swallowing, eating, drinking, and mechanical movement rapidly clear substances from the mouth. A compound that binds a virus in a static lab dish may not remain in contact with oral tissues long enough to work in a real person.
-
Anatomical Reach: Oropharyngeal cancers often develop deep within tissue crevices, such as the tonsillar crypts or the base of the tongue. It remains unproven whether chewing a gum can deliver active proteins effectively to these hard-to-reach areas.
-
Viral Clearing vs. Cancer Prevention: Reducing viral load in a fluid sample is fundamentally different from preventing cancer. Cancer development involves complex, multi-year biological processes involving cellular mutation, immune suppression, genetics, and environmental exposures. Lowering temporary viral levels does not automatically translate into a reduction in persistent infection or pre-cancerous lesions.
Furthermore, the study does not show that the experimental gum can shrink existing tumors, improve survival rates, or substitute for established treatments like surgery, radiation, or chemotherapy.
Practical Takeaways for Consumers and Patients
For health-conscious consumers, the main message is clear: over-the-counter chewing gum will not protect against HPV or oral cancer. Commercial chewing gums do not contain the specialized protein formulations tested in this trial.
To effectively lower head and neck cancer risk, public health agencies recommend sticking to proven, evidence-based practices:
-
Get Vaccinated: The HPV vaccine is an established, highly effective tool for preventing new infections from high-risk HPV strains known to cause cancer. (Note: Vaccination prevents new infections but does not cure existing ones.)
-
Avoid Tobacco and Areca Nut: Eliminate cigarettes, cigars, smokeless tobacco, and betel quid, all of which introduce severe carcinogens to oral tissue.
-
Moderate Alcohol Use: Limit alcohol intake, as combining alcohol with tobacco exponentially increases oral cancer risk.
-
Maintain Oral Hygiene: Brush and floss daily, and schedule regular dental checkups to catch oral tissue changes early.
-
Recognize Warning Signs: Consult a doctor or dentist promptly if you experience persistent mouth sores, unexplained oral bleeding, a lump in the neck, persistent sore throat, hoarseness, or difficulty swallowing that lasts longer than two weeks.
For clinicians, this research represents a promising early step toward localized drug delivery that spares the broader microbiome. However, rigorous clinical trials in humans will be required to establish safety, ideal dosage, side effects, and actual clinical benefit before any medical chewing gum reaches pharmacy shelves.
References
-
https://www.ndtv.com/health/can-a-chewing-gum-help-reduce-risk-of-head-and-neck-cancer-new-study-says-yes-11870696
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
